Introduction of diabetic nephropathy

出自KMU Wiki

(修訂版本間差異)
跳轉到: 導航, 搜索
在2018年3月27日 (二) 12:42所做的修訂版本 (編輯)
Guhjy (對話 | 貢獻)

←上一個
當前修訂版本 (2018年3月27日 (二) 12:43) (編輯) (撤銷)
Guhjy (對話 | 貢獻)

 
第10行: 第10行:
*** [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-3TX4KPJ-3&_user=2411013&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000051939&_version=1&_urlVersion=0&_userid=2411013&md5=6ce6fc1e30dcd65072e0b0bc72934dff| Lancet 1998;352:837. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)] *** [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-3TX4KPJ-3&_user=2411013&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000051939&_version=1&_urlVersion=0&_userid=2411013&md5=6ce6fc1e30dcd65072e0b0bc72934dff| Lancet 1998;352:837. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)]
***Type 2 DM ***Type 2 DM
-**Intensive glycemic control prevents microangiopathy in newly diagnosed DM, but effects on macroangiopathy (cardiovascular diseases and atherosclerosis) are less certain+**Intensive glycemic control (HbA1C 6.5~7%) prevents microangiopathy in newly diagnosed DM, but effects on macroangiopathy (cardiovascular diseases and atherosclerosis) are less certain

當前修訂版本